The trinity of COVID-19: immunity, inflammation and intervention (original) (raw)

• World Health Organization. WHO Director-General’s opening remarks at the media briefing on COVID-19 - 11 March 2020. WHO https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020 (2020).
• Fehr, A. R. & Perlman, S. Coronaviruses: an overview of their replication and pathogenesis. Methods. Mol. Biol. 1282, 1–23 (2015).
  Article CAS PubMed PubMed Central Google Scholar
• Coronaviridae Study Group of the International Committee on Taxonomy of Viruses. The species severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat. Microbiol. 5, 536–544 (2020).
  Article CAS Google Scholar
• Zhou, P. et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579, 270–273 (2020).
  Article CAS PubMed PubMed Central Google Scholar
• Andersen, K. G., Rambaut, A., Lipkin, W. I., Holmes, E. C. & Garry, R. F. The proximal origin of SARS-CoV-2. Nat. Med. https://doi.org/10.1038/s41591-020-0820-9 (2020).
  Article PubMed PubMed Central Google Scholar
• Guan, W. J. et al. Clinical characteristics of coronavirus disease 2019 in China. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa2002032 (2020).
  Article PubMed PubMed Central Google Scholar
• Pung, R. et al. Investigation of three clusters of COVID-19 in Singapore: implications for surveillance and response measures. Lancet 395, 1039–1046 (2020).
  Article CAS PubMed PubMed Central Google Scholar
• Lauer, S. A. et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann. Intern. Med. https://doi.org/10.7326/m20-0504 (2020).
  Article PubMed PubMed Central Google Scholar
• Li, Q. et al. Early transmission dynamics in Wuhan, China, of Novel Coronavirus-infected pneumonia. N. Engl. J. Med. 382, 1199–1207 (2020).
  Article CAS PubMed PubMed Central Google Scholar
• Chan, J. F. et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet 395, 514–523 (2020).
  Article CAS PubMed PubMed Central Google Scholar
• Huang, C. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395, 497–506 (2020). This prospective study is the earliest to include an analysis of cytokine levels in severe and mild COVID-19, showing the presence of a cytokine storm analogous to that found for SARS-CoV infection.
  Article CAS PubMed PubMed Central Google Scholar
• Chen, G. et al. Clinical and immunologic features of severe and moderate coronavirus disease 2019. J. Clin. Invest. https://doi.org/10.1172/jci137244 (2020).
  Article CAS PubMed PubMed Central Google Scholar
• Liu, Y. et al. Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury. Sci. China Life Sci. 63, 364–374 (2020).
  Article CAS PubMed PubMed Central Google Scholar
• Chen, N. et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 395, 507–513 (2020).
  Article CAS PubMed PubMed Central Google Scholar
• Phan, L. T. et al. Importation and human-to-human transmission of a novel coronavirus in Vietnam. N. Engl. J. Med. 382, 872–874 (2020).
  Article PubMed PubMed Central Google Scholar
• Pan, Y., Zhang, D., Yang, P., Poon, L. L. M. & Wang, Q. Viral load of SARS-CoV-2 in clinical samples. Lancet Infect. Dis. https://doi.org/10.1016/s1473-3099(20)30113-4 (2020).
  Article PubMed PubMed Central Google Scholar
• Kim, J. Y. et al. Viral load kinetics of SARS-CoV-2 infection in first two patients in Korea. J. Korean Med. Sci. 35, e86 (2020).
  Article CAS PubMed PubMed Central Google Scholar
• Zou, L. et al. SARS-CoV-2 viral load in upper respiratory specimens of infected patients. N. Engl. J. Med. 382, 1177–1179 (2020).
  Article PubMed PubMed Central Google Scholar
• Peiris, J. S. et al. Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study. Lancet 361, 1767–1772 (2003).
  Article CAS PubMed PubMed Central Google Scholar
• Wang, D. et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 323, 1061–1069 (2020).
  Article CAS PubMed PubMed Central Google Scholar
• Wong, C. K. et al. Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome. Clin. Exp. Immunol. 136, 95–103 (2004).
  Article CAS PubMed PubMed Central Google Scholar
• Zhang, B. et al. Clinical characteristics of 82 death cases with COVID-19. Preprint at medRxiv https://doi.org/10.1101/2020.02.26.20028191 (2020).
• Chu, K. H. et al. Acute renal impairment in coronavirus-associated severe acute respiratory syndrome. Kidney Int. 67, 698–705 (2005).
  Article PubMed PubMed Central Google Scholar
• Jia, H. P. et al. ACE2 receptor expression and severe acute respiratory syndrome coronavirus infection depend on differentiation of human airway epithelia. J. Virol. 79, 14614–14621 (2005).
  Article CAS PubMed PubMed Central Google Scholar
• Xu, H. et al. High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa. Int. J. Oral. Sci. 12, 8 (2020).
  Article CAS PubMed PubMed Central Google Scholar
• Hamming, I. et al. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J. Pathol. 203, 631–637 (2004).
  Article CAS PubMed PubMed Central Google Scholar
• Zhao, Y. et al. Single-cell RNA expression profiling of ACE2, the putative receptor of Wuhan 2019-nCov. Preprint at bioRxiv https://doi.org/10.1101/2020.01.26.919985 (2020).
• Walls, A. C. et al. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell https://doi.org/10.1016/j.cell.2020.02.058 (2020). Together with Wrapp et al. (2020), this article presents a cryo-electron microscopy structure of the SARS-CoV-2 spike glycoprotein used for cell entry, including an analysis of its receptor-binding kinetics and antigenicity with respect to SARS-CoV.
  Article PubMed PubMed Central Google Scholar
• Imai, Y. et al. Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature 436, 112–116 (2005).
  Article CAS PubMed PubMed Central Google Scholar
• Imai, Y., Kuba, K. & Penninger, J. M. The discovery of angiotensin-converting enzyme 2 and its role in acute lung injury in mice. Exp. Physiol. 93, 543–548 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Kuba, K. et al. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. Nat. Med. 11, 875–879 (2005).
  Article CAS PubMed PubMed Central Google Scholar
• Kuba, K., Imai, Y. & Penninger, J. M. Angiotensin-converting enzyme 2 in lung diseases. Curr. Opin. Pharmacol. 6, 271–276 (2006).
  Article CAS PubMed PubMed Central Google Scholar
• Epidemiology Working Group for NCIP Epidemic Response. The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China. Chin. J. Epidemiol. 41, 145–151 (2020).
  Google Scholar
• Taneja, V. Sex hormones determine immune response. Front. Immunol. 9, 1931 (2018).
  Article PubMed PubMed Central CAS Google Scholar
• Xiao, X., Chakraborti, S., Dimitrov, A. S., Gramatikoff, K. & Dimitrov, D. S. The SARS-CoV S glycoprotein: expression and functional characterization. Biochem. Biophys. Res. Commun. 312, 1159–1164 (2003).
  Article CAS PubMed PubMed Central Google Scholar
• Babcock, G. J., Esshaki, D. J., Thomas, W. D. Jr. & Ambrosino, D. M. Amino acids 270 to 510 of the severe acute respiratory syndrome coronavirus spike protein are required for interaction with receptor. J. Virol. 78, 4552–4560 (2004).
  Article CAS PubMed PubMed Central Google Scholar
• Wong, S. K., Li, W., Moore, M. J., Choe, H. & Farzan, M. A 193-amino acid fragment of the SARS coronavirus S protein efficiently binds angiotensin-converting enzyme 2. J. Biol. Chem. 279, 3197–3201 (2004).
  Article CAS PubMed Google Scholar
• Simmons, G. et al. Inhibitors of cathepsin L prevent severe acute respiratory syndrome coronavirus entry. Proc. Natl Acad. Sci. USA 102, 11876–11881 (2005).
  Article CAS PubMed PubMed Central Google Scholar
• Bosch, B. J. et al. Severe acute respiratory syndrome coronavirus (SARS-CoV) infection inhibition using spike protein heptad repeat-derived peptides. Proc. Natl Acad. Sci. USA 101, 8455–8460 (2004).
  Article CAS PubMed PubMed Central Google Scholar
• Liu, S. et al. Interaction between heptad repeat 1 and 2 regions in spike protein of SARS-associated coronavirus: implications for virus fusogenic mechanism and identification of fusion inhibitors. Lancet 363, 938–947 (2004).
  Article CAS PubMed PubMed Central Google Scholar
• Chen, Y., Guo, Y., Pan, Y. & Zhao, Z. J. Structure analysis of the receptor binding of 2019-nCoV. Biochem. Biophys. Res. Commun. 525, 135–140 (2020).
  Article CAS PubMed Central Google Scholar
• Wrapp, D. et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science 367, 1260–1263 (2020). Together with Walls et al. (2020), this article presents a high-resolution cryo-electron microscopy structure of the SARS-CoV-2 spike glycoprotein used for cell entry, including an analysis of its receptor-binding kinetics with respect to SARS-CoV.
  Article CAS PubMed PubMed Central Google Scholar
• Coutard, B. et al. The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade. Antivir. Res. 176, 104742 (2020).
  Article CAS PubMed Google Scholar
• Hoffmann, M. et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell https://doi.org/10.1016/j.cell.2020.02.052 (2020).
  Article PubMed PubMed Central Google Scholar
• Richardson, P. et al. Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. Lancet 395, e30–e31 (2020).
  Article CAS PubMed PubMed Central Google Scholar
• Chinese Clinical Trial Register. Chictr.org.cn http://www.chictr.org.cn/showprojen.aspx?proj=49088 (2020).
• Pipeline Review. APEIRON’s respiratory drug product to start pilot clinical trial to treat coronavirus disease COVID-19 in China. Pipeline Review https://pipelinereview.com/index.php/2020022673884/Proteins-and-Peptides/APEIRONs-respiratory-drug-product-to-start-pilot-clinical-trial-to-treat-coronavirus-disease-COVID-19-in-China.html (2020).
• Wang, M. et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 30, 269–271 (2020).
  Article CAS PubMed PubMed Central Google Scholar
• Yamamoto, M. et al. Identification of nafamostat as a potent inhibitor of Middle East respiratory syndrome coronavirus S protein-mediated membrane fusion using the split-protein-based cell-cell fusion assay. Antimicrob. Agents Chemother. 60, 6532–6539 (2016).
  Article CAS PubMed PubMed Central Google Scholar
• Zhang, H., Penninger, J. M., Li, Y., Zhong, N. & Slutsky, A. S. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. Intensive Care Med. 46, 586–590 (2020).
  Article CAS PubMed PubMed Central Google Scholar
• Park, W. B. et al. Virus isolation from the first patient with SARS-CoV-2 in Korea. J. Korean Med. Sci. 35, e84 (2020).
  Article CAS PubMed PubMed Central Google Scholar
• Zhang, H. et al. Histopathologic changes and SARS-CoV-2 immunostaining in the lung of a patient with COVID-19. Ann. Intern. Med. https://doi.org/10.7326/m20-0533 (2020).
  Article PubMed PubMed Central Google Scholar
• Chen, I. Y., Moriyama, M., Chang, M. F. & Ichinohe, T. Severe acute respiratory syndrome coronavirus viroporin 3a activates the NLRP3 inflammasome. Front. Microbiol. 10, 50 (2019).
  Article PubMed PubMed Central Google Scholar
• Fink, S. L. & Cookson, B. T. Apoptosis, pyroptosis, and necrosis: mechanistic description of dead and dying eukaryotic cells. Infect. Immun. 73, 1907–1916 (2005).
  Article CAS PubMed PubMed Central Google Scholar
• Yang, M. Cell pyroptosis, a potential pathogenic mechanism of 2019-nCoV infection. SSRN https://doi.org/10.2139/ssrn.3527420 (2020).
• Huang, K. J. et al. An interferon-gamma-related cytokine storm in SARS patients. J. Med. Virol. 75, 185–194 (2005).
  Article CAS PubMed Google Scholar
• Xu, Z. et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir. Med. 8, 420–422 (2020). This study is the first to describe pathological findings in severe COVID-19 and demonstrates the aberrant immune cell infiltrates found in the lung.
  Article CAS PubMed PubMed Central Google Scholar
• Tian, S. et al. Pulmonary pathology of early phase 2019 novel coronavirus (COVID-19) pneumonia in two patients with lung cancer. J. Thorac. Oncol. https://doi.org/10.1016/j.jtho.2020.02.010 (2020).
  Article PubMed PubMed Central Google Scholar
• Qin, C. et al. Dysregulation of immune response in patients with COVID-19 in Wuhan, China. Clin. Infect. Dis. https://doi.org/10.1093/cid/ciaa248 (2020).
  Article PubMed PubMed Central Google Scholar
• Zhou, F. et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 395, 1054–1062 (2020).
  Article CAS PubMed PubMed Central Google Scholar
• Liao, M. et al. The landscape of lung bronchoalveolar immune cells in COVID-19 revealed by single-cell RNA sequencing. Preprint at medRxiv https://doi.org/10.1101/2020.02.23.20026690 (2020).
• Zhou, Y. et al. Pathogenic T cells and inflammatory monocytes incite inflammatory storm in severe COVID-19 patients. Natl Sci. Rev. https://doi.org/10.1093/nsr/nwaa041 (2020).
  Article PubMed Central PubMed Google Scholar
• Siu, K. L., Chan, C. P., Kok, K. H., Chiu-Yat Woo, P. & Jin, D. Y. Suppression of innate antiviral response by severe acute respiratory syndrome coronavirus M protein is mediated through the first transmembrane domain. Cell. Mol. Immunol. 11, 141–149 (2014).
  Article CAS PubMed PubMed Central Google Scholar
• Versteeg, G. A., Bredenbeek, P. J., van den Worm, S. H. & Spaan, W. J. Group 2 coronaviruses prevent immediate early interferon induction by protection of viral RNA from host cell recognition. Virology 361, 18–26 (2007).
  Article CAS PubMed Google Scholar
• Sun, L. et al. Coronavirus papain-like proteases negatively regulate antiviral innate immune response through disruption of STING-mediated signaling. PLoS One 7, e30802 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Frieman, M., Ratia, K., Johnston, R. E., Mesecar, A. D. & Baric, R. S. Severe acute respiratory syndrome coronavirus papain-like protease ubiquitin-like domain and catalytic domain regulate antagonism of IRF3 and NF-kappaB signaling. J. Virol. 83, 6689–6705 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Frieman, M. et al. Severe acute respiratory syndrome coronavirus ORF6 antagonizes STAT1 function by sequestering nuclear import factors on the rough endoplasmic reticulum/Golgi membrane. J. Virol. 81, 9812–9824 (2007).
  Article CAS PubMed PubMed Central Google Scholar
• Narayanan, K. et al. Severe acute respiratory syndrome coronavirus nsp1 suppresses host gene expression, including that of type I interferon, in infected cells. J. Virol. 82, 4471–4479 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Ruan, Q., Yang, K., Wang, W., Jiang, L. & Song, J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. https://doi.org/10.1007/s00134-020-05991-x (2020).
  Article PubMed PubMed Central Google Scholar
• Zhao, J., Zhao, J., Legge, K. & Perlman, S. Age-related increases in PGD2 expression impair respiratory DC migration, resulting in diminished T cell responses upon respiratory virus infection in mice. J. Clin. Invest. 121, 4921–4930 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Kam, K. Q. et al. A well infant with coronavirus disease 2019 (COVID-19) with high viral load. Clin. Infect. Dis. https://doi.org/10.1093/cid/ciaa201 (2020).
  Article PubMed Google Scholar
• Dong, Y. et al. Epidemiological characteristics of 2143 pediatric patients with 2019 coronavirus disease in China. Pediatrics https://doi.org/10.1542/peds.2020-0702 (2020).
  Article PubMed PubMed Central Google Scholar
• Gu, J. et al. Multiple organ infection and the pathogenesis of SARS. J. Exp. Med. 202, 415–424 (2005). This article describes the presence of SARS-CoV viral particles and RNA in T cells, monocytes and macrophages, suggesting that SARS-CoV and potentially SARS-CoV-2 may drive immunopathogenesis by direct infection of immune cells.
  Article CAS PubMed PubMed Central Google Scholar
• Cheung, C. Y. et al. Cytokine responses in severe acute respiratory syndrome coronavirus-infected macrophages in vitro: possible relevance to pathogenesis. J. Virol. 79, 7819–7826 (2005).
  Article CAS PubMed PubMed Central Google Scholar
• Yilla, M. et al. SARS-coronavirus replication in human peripheral monocytes/macrophages. Virus Res. 107, 93–101 (2005).
  Article CAS PubMed Google Scholar
• Tseng, C. T., Perrone, L. A., Zhu, H., Makino, S. & Peters, C. J. Severe acute respiratory syndrome and the innate immune responses: modulation of effector cell function without productive infection. J. Immunol. 174, 7977–7985 (2005).
  Article CAS PubMed Google Scholar
• Law, H. K. et al. Chemokine up-regulation in SARS-coronavirus-infected, monocyte-derived human dendritic cells. Blood 106, 2366–2374 (2005).
  Article CAS PubMed Google Scholar
• US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT04273321 (2020).
• Stockman, L. J., Bellamy, R. & Garner, P. SARS: systematic review of treatment effects. PLoS Med. 3, e343 (2006).
  Article PubMed PubMed Central CAS Google Scholar
• Tai, D. Y. Pharmacologic treatment of SARS: current knowledge and recommendations. Ann. Acad. Med. Singap. 36, 438–443 (2007).
  PubMed Google Scholar
• Chinese Clinical Trial Register. Chictr.org.cn http://www.chictr.org.cn/showproj.aspx?proj=49409 (2020).
• Liu, A. China turns Roche arthritis drug Actemra against COVID-19 in new treatment guidelines. FiercePharma https://www.fiercepharma.com/pharma-asia/china-turns-roche-arthritis-drug-actemra-against-covid-19-new-treatment-guidelines (2020).
• Roivant Sciences. Roivant announces development of anti-GM-CSF monoclonal antibody to prevent and treat acute respiratory distress syndrome (ARDS) in patients with COVID-19. Roivant Sciences https://roivant.com/roivant-announces-development-of-anti-gm-csf-monoclonal-antibody-to-prevent-and-treat-acute-respiratory-distress-syndrome-ards-in-patients-with-covid-19/ (2020).
• Humanigen. Humanigen partners with CTI, a leading contract research organization, for planned phase III study for lenzilumab for coronavirus treatment. Humanigen https://www.humanigen.com/press/Humanigen-Partners-With-CTI%2C-A-Leading-Contract-Research-Organization%2C-For-Planned-Phase-III-Study-For-Lenzilumab-For-Coronavirus-Treatment (2020).
• Izana Bioscience. Initiation of two-centre compassionate use study involving namilumab in the treatment of individual patients with rapidly worsening COVID-19 infection in Italy. Izana Bioscience https://izanabio.com/initiation- of-two-centre-compassionate-use-study-involving-namilumab-in-the-treatment-of-individual-patients-with-rapidly-worsening-covid-19-infection-in-italy/ (2020).
• CytoSorbents Corportation. CytoSorb, the Wuhan coronavirus, and cytokine storm_._ PR Newswire https://www.prnewswire.com/news-releases/cytosorb-the-wuhan-coronavirus-and-cytokine-storm-300994196.html (2020).
• Chen, C. et al. Thalidomide combined with low-dose glucocorticoid in the treatment of COVID-19 pneumonia. Preprints https://www.preprints.org/manuscript/202002.0395/v1 (2020).
• US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT04273581 (2020).
• US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT04273529 (2020).
• Tobinick, E. TNF-alpha inhibition for potential therapeutic modulation of SARS coronavirus infection. Curr. Med. Res. Opin. 20, 39–40 (2004).
  Article CAS PubMed Google Scholar
• Gautret, P. et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int. J. Antimicrob. Agents https://doi.org/10.1016/j.ijantimicag.2020.105949 (2020).
  Article PubMed PubMed Central Google Scholar
• Yao, X. et al. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin. Infect. Dis. https://doi.org/10.1093/cid/ciaa237 (2020).
  Article PubMed PubMed Central Google Scholar
• Shukla, A. M. & Wagle Shukla, A. Expanding horizons for clinical applications of chloroquine, hydroxychloroquine, and related structural analogues. Drugs Context. 8, 2019-9-1 (2019).
  Article PubMed PubMed Central Google Scholar
• Cortegiani, A., Ingoglia, G., Ippolito, M., Giarratano, A. & Einav, S. A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19. J. Crit. Care https://doi.org/10.1016/j.jcrc.2020.03.005 (2020).
  Article PubMed PubMed Central Google Scholar
• Wong, R. S. et al. Haematological manifestations in patients with severe acute respiratory syndrome: retrospective analysis. BMJ 326, 1358–1362 (2003).
  Article PubMed PubMed Central Google Scholar
• Cui, W. et al. Expression of lymphocytes and lymphocyte subsets in patients with severe acute respiratory syndrome. Clin. Infect. Dis. 37, 857–859 (2003).
  Article PubMed Google Scholar
• Li, T. et al. Significant changes of peripheral T lymphocyte subsets in patients with severe acute respiratory syndrome. J. Infect. Dis. 189, 648–651 (2004).
  Article PubMed Google Scholar
• Zheng, H.-Y. et al. Elevated exhaustion levels and reduced functional diversity of T cells in peripheral blood may predict severe progression in COVID-19 patients. Cell. Mol. Immunol. https://doi.org/10.1038/s41423-020-0401-3 (2020). This article examines the immune states of patients with severe or mild COVID-19 and shows reduced T cell functional diversity in severe COVID-19, supporting a role for T cell function in controlling COVID-19.
  Article PubMed PubMed Central Google Scholar
• Libraty, D. H., O’Neil, K. M., Baker, L. M., Acosta, L. P. & Olveda, R. M. Human CD4+ memory T-lymphocyte responses to SARS coronavirus infection. Virology 368, 317–321 (2007).
  Article CAS PubMed Google Scholar
• Yang, L. T. et al. Long-lived effector/central memory T-cell responses to severe acute respiratory syndrome coronavirus (SARS-CoV) S antigen in recovered SARS patients. Clin. Immunol. 120, 171–178 (2006).
  Article CAS PubMed PubMed Central Google Scholar
• Oh, H. L. J., Gan, K.-E. S., Bertoletti, A. & Tan, Y. J. Understanding the T cell immune response in SARS coronavirus infection. Emerg. Microbes. Infect. 1, e23 (2012).
  CAS Google Scholar
• Shin, H. S. et al. Immune responses to Middle East respiratory syndrome coronavirus during the acute and convalescent phases of human infection. Clin. Infect. Dis. 68, 984–992 (2019).
  Article CAS PubMed Google Scholar
• Chen, J. et al. Cellular immune responses to severe acute respiratory syndrome coronavirus (SARS-CoV) infection in senescent BALB/c mice: CD4+ T cells are important in control of SARS-CoV infection. J. Virol. 84, 1289–1301 (2010).
  Article CAS PubMed Google Scholar
• Roberts, A. et al. A mouse-adapted SARS-coronavirus causes disease and mortality in BALB/c mice. PLoS Pathog. 3, e5 (2007).
  Article PubMed PubMed Central CAS Google Scholar
• Zhao, J., Zhao, J. & Perlman, S. T cell responses are required for protection from clinical disease and for virus clearance in severe acute respiratory syndrome coronavirus-infected mice. J. Virol. 84, 9318–9325 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Deming, D. et al. Vaccine efficacy in senescent mice challenged with recombinant SARS-CoV bearing epidemic and zoonotic spike variants. PLoS Med. 3, e525 (2006).
  Article PubMed PubMed Central CAS Google Scholar
• Yasui, F. et al. Prior immunization with severe acute respiratory syndrome (SARS)-associated coronavirus (SARS-CoV) nucleocapsid protein causes severe pneumonia in mice infected with SARS-CoV. J. Immunol. 181, 6337–6348 (2008).
  Article CAS PubMed Google Scholar
• Bolles, M. et al. A double-inactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces increased eosinophilic proinflammatory pulmonary response upon challenge. J. Virol. 85, 12201–12215 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Lurie, N., Saville, M., Hatchett, R. & Halton, J. Developing Covid-19 vaccines at pandemic speed. N. Engl. J. Med. https://doi.org/10.1056/NEJMp2005630 (2020).
  Article PubMed Google Scholar
• Thevarajan, I. et al. Breadth of concomitant immune responses prior to patient recovery: a case report of non-severe COVID-19. Nat. Med. https://doi.org/10.1038/s41591-020-0819-2 (2020).
  Article PubMed PubMed Central Google Scholar
• Tan, Y. J. et al. Profiles of antibody responses against severe acute respiratory syndrome coronavirus recombinant proteins and their potential use as diagnostic markers. Clin. Diagn. Lab. Immunol. 11, 362–371 (2004).
  Article CAS PubMed PubMed Central Google Scholar
• Wu, H. S. et al. Early detection of antibodies against various structural proteins of the SARS-associated coronavirus in SARS patients. J. Biomed. Sci. 11, 117–126 (2004).
  Article CAS PubMed Google Scholar
• Nie, Y. et al. Neutralizing antibodies in patients with severe acute respiratory syndrome-associated coronavirus infection. J. Infect. Dis. 190, 1119–1126 (2004).
  Article PubMed Google Scholar
• Temperton, N. J. et al. Longitudinally profiling neutralizing antibody response to SARS coronavirus with pseudotypes. Emerg. Infect. Dis. 11, 411–416 (2005).
  Article PubMed PubMed Central Google Scholar
• CGTN. Expert: recovered coronavirus patients are still prone to reinfection. YouTube https://www.youtube.com/watch?v=GZ99J7mlaIQ (2020).
• The Straits Times. Japanese woman reinfected with coronavirus weeks after initial recovery. The Straits Times https://www.straitstimes.com/asia/east-asia/japanese-woman-reinfected-with-coronavirus-weeks-after-initial-recovery (2020).
• NHK World-Japan. Japanese man tests positive for coronavirus again. NHK https://www3.nhk.or.jp/nhkworld/en/news/20200315_13/ (2020).
• Xinhua. China puts 245 COVID-19 patients on convalescent plasma therapy. Xinhuanet http://www.xinhuanet.com/english/2020-02/28/c_138828177.htm (2020).
• Cheng, Y. et al. Use of convalescent plasma therapy in SARS patients in Hong Kong. Eur. J. Clin. Microbiol. Infect. Dis. 24, 44–46 (2005).
  Article CAS PubMed Google Scholar
• Soo, Y. O. et al. Retrospective comparison of convalescent plasma with continuing high-dose methylprednisolone treatment in SARS patients. Clin. Microbiol. Infect. 10, 676–678 (2004).
  Article CAS PubMed PubMed Central Google Scholar
• Yeh, K. M. et al. Experience of using convalescent plasma for severe acute respiratory syndrome among healthcare workers in a Taiwan hospital. J. Antimicrob. Chemother. 56, 919–922 (2005).
  Article CAS PubMed Google Scholar
• Zhu, Z. et al. Potent cross-reactive neutralization of SARS coronavirus isolates by human monoclonal antibodies. Proc. Natl Acad. Sci. USA 104, 12123–12128 (2007).
  Article CAS PubMed PubMed Central Google Scholar
• Wang, C. et al. A human monoclonal antibody blocking SARS-CoV-2 infection. Preprint at bioRxiv https://doi.org/10.1101/2020.03.11.987958 (2020).
• Tian, X. et al. Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody. Emerg. Microbes Infect. 9, 382–385 (2020).
  Article CAS PubMed PubMed Central Google Scholar
• Li, F., Li, W., Farzan, M. & Harrison, S. C. Structure of SARS coronavirus spike receptor-binding domain complexed with receptor. Science 309, 1864–1868 (2005).
  Article CAS PubMed Google Scholar
• Tai, W. et al. Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine. Cell. Mol. Immunology https://doi.org/10.1038/s41423-020-0400-4 (2020).
  Article Google Scholar
• Li, X. Y. et al. The keypoints in treatment of the critical coronavirus disease 2019 patient. Chin. J. Tuberculosis Respir. Dis. 43, E026 (2020).
  Google Scholar
• CNA. Chinese doctors ‘using plasma therapy’ on COVID-19 patients. CNA https://www.channelnewsasia.com/news/asia/chinese-doctors-using-plasma-therapy-on-covid-19-patients-12444244 (2020).
• Johnson, R. F. et al. 3B11-N, a monoclonal antibody against MERS-CoV, reduces lung pathology in rhesus monkeys following intratracheal inoculation of MERS-CoV Jordan-n3/2012. Virology 490, 49–58 (2016).
  Article CAS PubMed Google Scholar
• VIR. Press release details: Vir Biotechnology applying multiple platforms to address public health risk from Wuhan coronavirus. VIR https://investors.vir.bio/news-releases/news-release-details/vir-biotechnology-applying-multiple-platforms-address-public (2020).
• Cohen, J. Can an anti-HIV combination or other existing drugs outwit the new coronavirus? Science https://www.sciencemag.org/news/2020/01/can-anti-hiv-combination-or-other-existing-drugs-outwit-new-coronavirus (2020).
• Duddu, P. Coronavirus treatment: vaccines/drugs in the pipeline for COVID-19. Clinical Trials Arena https://www.clinicaltrialsarena.com/analysis/coronavirus-mers-cov-drugs/ (2020).
• Berry, J. D. et al. Neutralizing epitopes of the SARS-CoV S-protein cluster independent of repertoire, antigen structure or mAb technology. MAbs 2, 53–66 (2010). This article shows the immunodominance of neutralizing epitopes on the RBD for SARS-CoV, suggesting the feasibility of a recombinant antigen strategy focused on the RBD for vaccination against COVID-19.
  Article PubMed PubMed Central Google Scholar
• Qiu, M. et al. Antibody responses to individual proteins of SARS coronavirus and their neutralization activities. Microbes Infect. 7, 882–889 (2005).
  Article CAS PubMed PubMed Central Google Scholar
• GISAID. Receptor binding surveillance for high quality genomes. GISAID https://www.gisaid.org/ (2020).
• Kleine-Weber, H. et al. Mutations in the spike protein of Middle East respiratory syndrome coronavirus transmitted in Korea increase resistance to antibody-mediated neutralization. J. Virol. 93, e01381-18 (2019).
  Article PubMed PubMed Central Google Scholar
• Rockx, B. et al. Escape from human monoclonal antibody neutralization affects in vitro and in vivo fitness of severe acute respiratory syndrome coronavirus. J. Infect. Dis. 201, 946–955 (2010).
  Article CAS PubMed Google Scholar
• Yang, Z. Y. et al. Evasion of antibody neutralization in emerging severe acute respiratory syndrome coronaviruses. Proc. Natl. Acad. Sci. USA 102, 797–801 (2005).
  Article CAS PubMed PubMed Central Google Scholar
• Ho, M. S. et al. Neutralizing antibody response and SARS severity. Emerg. Infect. Dis. 11, 1730–1737 (2005).
  Article CAS PubMed PubMed Central Google Scholar
• Tetro, J. A. Is COVID-19 receiving ADE from other coronaviruses? Microbes Infect. 22, 72–73 (2020).
  Article CAS PubMed PubMed Central Google Scholar
• Liu, L. et al. Anti-spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infection. JCI Insight https://doi.org/10.1172/jci.insight.123158 (2019).
  Article PubMed PubMed Central Google Scholar
• Zhang, L. et al. Antibody responses against SARS coronavirus are correlated with disease outcome of infected individuals. J. Med. Virol. 78, 1–8 (2006).
  Article CAS PubMed Google Scholar
• Arabi, Y. M. et al. Feasibility of using convalescent plasma immunotherapy for MERS-CoV infection, Saudi Arabia. Emerg. Infect. Dis. 22, 1554 (2016).
  Article CAS PubMed PubMed Central Google Scholar
• Drosten, C. et al. Transmission of MERS-coronavirus in household contacts. N. Engl. J. Med. 371, 828–835 (2014).
  Article PubMed CAS Google Scholar
• Park, W. B. et al. Kinetics of serologic responses to MERS coronavirus infection in humans, South Korea. Emerg. Infect. Dis. 21, 2186–2189 (2015).
  Article CAS PubMed PubMed Central Google Scholar
• Nimmerjahn, F. & Ravetch, J. V. Fcgamma receptors as regulators of immune responses. Nat. Rev. Immunol. 8, 34–47 (2008).
  Article CAS PubMed Google Scholar
• Bournazos, S., DiLillo, D. J. & Ravetch, J. V. The role of Fc-FcgammaR interactions in IgG-mediated microbial neutralization. J. Exp. Med. 212, 1361–1369 (2015).
  Article CAS PubMed PubMed Central Google Scholar
• Kaneko, Y., Nimmerjahn, F. & Ravetch, J. V. Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science 313, 670–673 (2006).
  Article CAS PubMed Google Scholar
• Zhang, Q., Wang, Y., Qi, C., Shen, L. & Li, J. Clinical trial analysis of 2019-nCoV therapy registered in China. J. Med. Virol. https://doi.org/10.1002/jmv.25733 (2020).
  Article PubMed PubMed Central Google Scholar
• Shang, J. et al. Structural basis of receptor recognition by SARS-CoV-2. Nature https://doi.org/10.1038/s41586-020-2179-y (2020).
  Article PubMed PubMed Central Google Scholar
• Prabakaran, P. et al. Structure of severe acute respiratory syndrome coronavirus receptor-binding domain complexed with neutralizing antibody. J. Biol. Chem. 281, 15829–15836 (2006).
  Article CAS PubMed Google Scholar